Japan industry group to examine clinical site cost discrepancies

By Gareth Macdonald contact

- Last updated on GMT

© Getty Images / itasun
© Getty Images / itasun

Related tags: Clinical trial

Japanese industry group JPMA has opted for cloud-based tech to help it understand why the cost of running a trial in the country varies depending on the site involved.

The Japan Pharmaceutical Manufacturers Association (JPMA) announced the project today, explaining that it will use Medidata software to model site-to-site cost variation and compare the findings with data from the UK, the US and 17 Asia-Pacific countries.

The collaboration follows a JPMA report (here​ in Japanese) highlighting the various cost calculations and payment methods in use at different investigator sites, which it suggests are holding back drug development in the country.

Shingo Haseto, leader of the JPMA’s clinical evaluation taskforce, said: “As the Japanese clinical trial landscape evolves, it is increasingly important that we ensure consistent and fair payment—both for sponsors and sites.”

He added that a better understanding of the cost discrepancies will result in “increased transparency around clinical trial costs related to site performance.”

J-GCP vs ICH-GCP

Japan has its own good clinical practice standard – J-GCP – which while similar to International Conference on Harmonisation GCP standards (ICH-GCP) differ in some key respects​.

The key differences – as they apply to trial sites in Japan – is the requirement that, in most cases, sites have their own institutional review board and the rule that site heads are responsible for signing all financial contracts.

Related news

Show more

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars